About Novuma®
Novuma® is an advanced calcium hydroxylapatite (CaHA) dermal filler developed by Burgeon Biotechnology, a forward-thinking biopharmaceutical company specializing in regenerative aesthetics and injectable technologies. Designed for deep dermal and subdermal volumization, Novuma® offers immediate structural support with the added benefit of long-term collagen stimulation, delivering natural and durable rejuvenation.
Novuma® CaHA Filler
Novuma® is formulated with synthetic CaHA microspheres suspended in a biodegradable gel carrier. Upon injection, it provides instant volume correction while triggering neocollagenesis for sustained skin tightening and texture improvement. Its high-viscosity gel ensures excellent lifting capacity, contour definition, and integration into facial tissue. Free from animal-derived components and produced under strict GMP standards, Novuma® is a safe, biocompatible alternative for patients seeking both structural enhancement and regenerative effects.
Ideal for mid-to-deep facial augmentation, including jawline sculpting, cheek enhancement, and chin projection, Novuma® delivers immediate visible results with progressive improvement in skin quality over time. The collagen-inducing effects typically last 12–18 months, making it a powerful choice for long-term rejuvenation without the need for frequent re-treatments. Novuma® integrates seamlessly with combination therapies in holistic anti-aging protocols.
About Burgeon Biotechnology
Burgeon Biotechnology is a biopharma innovator committed to advancing medical aesthetics through science-backed solutions that merge cosmetic precision with regenerative outcomes. With a strong foundation in biomaterial research and injectable therapeutics, the company focuses on developing safe, effective, and clinically validated products. Novuma® represents Burgeon’s dedication to elevating dermal filler performance by combining volumizing power with biologic skin restoration, meeting the evolving needs of modern aesthetic medicine.